Mouse Programmed Death 1(PD-1)ELISA Kit

Code CSB-E13586m
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
programmed cell death 1
Alternative Names
Pdcd1 ELISA Kit; Pd1 ELISA Kit; Programmed cell death protein 1 ELISA Kit; Protein PD-1 ELISA Kit; mPD-1 ELISA Kit; CD antigen CD279 ELISA Kit
Abbreviation
PDCD1
Uniprot No.
Species
Mus musculus (Mouse)
Sample Types
serum, plasma, tissue homogenates, cell lysates
Detection Range
0.312 ng/mL-20 ng/mL
Sensitivity
0.078 ng/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cell Biology
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of mouse PD-1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 97
Range % 92-101
1:2 Average % 91
Range % 85-96
1:4 Average % 84
Range % 80-88
1:8 Average % 95
Range % 95-99
Recovery
The recovery of mouse PD-1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 101 96-107
EDTA plasma (n=4) 95 90-100
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected
20 2.652 2.528 2.590 2.430
10 2.121 2.009 2.065 1.905
5 1.439 1.417 1.428 1.268
2.5 0.994 0.952 0.973 0.813
1.25 0.651 0.680 0.666 0.506
0.625 0.384 0.375 0.380 0.220
0.312 0.256 0.261 0.259 0.099
0 0.163 0.156 0.160  
Materials provided
  • A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human PD-1 antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
  • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
  • One vial Biotin-labeled PD-1 antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
  • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
  • One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody.
  • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
  • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
  • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
  • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
  • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
  • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
  • An instruction manual
Materials not provided
  • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
  • An incubator can provide stable incubation conditions up to 37°C±5°C.
  • Centrifuge
  • Vortex
  • Squirt bottle, manifold dispenser, or automated microplate washer
  • Absorbent paper for blotting the microtiter plate
  • 50-300ul multi-channel micropipette
  • Pipette tips
  • Single-channel micropipette with different ranges
  • 100ml and 500ml graduated cylinders
  • Deionized or distilled water
  • Timer
  • Test tubes for dilution
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Mouse PDCD1 ELISA Kit was designed for the quantitative measurement of Mouse PDCD1 protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 0.312 ng/mL-20 ng/mL and the sensitivity is 0.078 ng/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands, such as CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival.
Gene References into Functions
  1. Oncolytic herpes virotherapy and PD-1 blockade in a murine rhabdomyosarcoma model is an efficient treatment strategy. PMID: 28539588
  2. These results show that PD-1 plays an inhibitory role during the naive-to-effector CD8 T cell transition and that the PD-1 pathway can also be modulated at this stage of T cell differentiation. PMID: 29654146
  3. Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer PMID: 29303012
  4. T-cell activation mediates the immunopreventive effects of anti-PD-1; PD-1 on T cells interacts with the PD-1 ligand PD-L1 on cancer cells PMID: 29018057
  5. these data show that PD-1 expression is an intrinsic property of brain-resident memory CD8 T cells in a persistent CNS viral infection PMID: 28829048
  6. Our results demonstrate that entinostat enhances the antitumor effect of PD-1 targeting through functional inhibition of MDSCs and a transition away from an immune-suppressive tumor microenvironment. These data provide a mechanistic rationale for the clinical testing and potential markers of response of this novel combination in solid tumor patients. PMID: 28698201
  7. synergism in cell death by Caspase-1- and RipK3 resulted in restriction of PD-1 and TIM3 expression on primed CD8(+) T cells, which promoted the survival of activated CD8(+) T cells. PMID: 28686578
  8. Tim-3 and PD-1 pathways play critical roles in regulating CD8(+) T cell function and maintaining normal pregnancy. PMID: 28331165
  9. Anti-PD-1/PD-L1 therapy inhibited CMT167 orthotopic lung tumors by 95%. .Silencing PD-L1 expression in CMT167 cells resulted in smaller orthotopic tumors that remained sensitive to anti-PD-L1 therapy, whereas implantation of CMT167 cells into PD-L1(-) mice blocked orthotopic tumor growth, indicating a role for PD-L1 in both the cancer cell and the microenvironment. PMID: 28819064
  10. Combination therapies that depend on checkpoint inhibitor antibodies (Abs) such as for PD-1 or its ligand (PD-L1) together with immune stimulatory agonist Abs like anti-OX40 are being tested in the clinic to achieve improved antitumor effects PMID: 28848055
  11. Inhibition of Fut8, a core fucosyltransferase, by genetic ablation or pharmacologic inhibition reduced cell-surface expression of PD-1 and enhanced T cell activation, leading to more efficient tumor eradication. PMID: 28768188
  12. An examination of the mechanisms of immunity behind this long-term protection in PD-1 knockout mice showed a key role for parasite-specific CD8(+) T cells even when CD4(+) T cells and B cells responded to re-infection. PMID: 27217330
  13. To test the in vivo activity of REGN2810, which does not cross-react with murine PD-1, knock-in mice were generated to express a hybrid protein containing the extracellular domain of human PD-1, and transmembrane and intracellular domains of mouse PD-1 PMID: 28265006
  14. The combination of tumor vaccination to induce high avidity tumor specific T cell responses and PD-1 blockade synergises to provide tumor therapy and 85% survival in the aggressive B16 melanoma model. PMID: 27825115
  15. Blockade of PD-1 with monoclonal antibody may be an effective treatment during the postoperative period for restoring surgery-induced immunosuppression. PMID: 28320090
  16. Data suggest that genetic or environmental factors that even moderately affect the expression of both PD-1 and FoxP3 can cause life-threatening autoimmune diseases by disrupting the T-cell homeostasis. PMID: 27410049
  17. Data (including data from studies in transgenic/knockout mice) suggest that T-cell expression of Mirn155 is required to limit melanoma growth; miR-155, Pdcd1, Pdcd1l1, and Ctla4 appear to regulate overlapping pathways promoting antitumor immunity. [Mirn155 = microRNA 155; Pdcd1 = programmed cell death 1 protein; Pdcd1l1 = programmed cell death 1 ligand 1 protein; Ctla4 = cytotoxic T-lymphocyte-associated protein 4] PMID: 28912267
  18. PD-1 plays a vital role in brain inflammation via regulation of Fgl-2 after ICH, and that manipulation of PD-1 might be a promising therapeutical target in ICH. PMID: 27717876
  19. The identification of the role for PD-1 in regulating B cell-dependent antitumor immunity to Tn antigen highlights an opportunity to develop new therapeutic strategies targeting tumor-associated carbohydrate antigens PMID: 27856425
  20. These findings suggest that PD-1 pathway blockade may reverse adaptive immune resistance following cyclic dinucleotide treatment, enhancing both local and systemic antitumor immunity. PMID: 27821498
  21. data suggest that increased expression of checkpoint blockade molecules PD-1 and CTLA-4 on donor T cells is not sufficient to prevent GvHD, and that cooperation between checkpoint blockade signaling by host cells and donor Tregs is necessary to limit GvHD in allo-HSCT recipients PMID: 28953925
  22. PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8(+) T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination PMID: 28939757
  23. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor may induce a preferential cytokine profile and T-cell differentiation phenotype for anti-lymphoma therapies. PMID: 28670716
  24. soluble PD-1 is elevated in critical illness and may represent a potential biomarker for Acute respiratory distress syndrome. PMID: 27835962
  25. Together, our results suggest an important role of PD-1 in glioma-induced immune escape, and provide translational evidence for the use of PD-1 blocking antibodies in human malignant gliomas. PMID: 28681455
  26. study found that Bcl6 positively regulates PD-1 expression by inhibiting the ability of T-bet/Tbx21 to repress Pdcd1 transcription. PMID: 28586108
  27. PD-L1 selectively enhances T cell-mediated immune responses, driving graft-versus-host disease lethality and suggesting a context-dependent function of the PD-1/PD-L1 axis PMID: 27294527
  28. PD-1 is required for maintaining the number, and hence function, of KLRG1(+) Group 2 innate lymphoid cells. PMID: 28490441
  29. this study shows that PD-1 regulates early glycolytic and mitochondrial alterations in virus-specific CD8+ T cells generated during infection, and represses transcriptional coactivator PGC-1alpha PMID: 27496729
  30. Our results suggest that anti-PD-1 antibody treatment has little effect on afatinib-induced lung injury. PMID: 28756224
  31. both mouse and human tumour-associated macrophages (TAM) express PD-1; TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers PMID: 28514441
  32. These data implicate a critical role for conserved region C (CR-C), a promoter proximal cis-regulatory element that is critical to PD-1 expression in vitro, in governing PD-1 expression, and a subsequent role in guiding CD8 T cell differentiation PMID: 27895178
  33. we provide evidence that indicates that the PD-1(+) fraction of DN T cells represents self-reactive cells. PMID: 27060346
  34. PD-1 receptor has a role in interacting with programmed cell death ligands and B7-1 PMID: 28270509
  35. PD-1 is upregulated in CD4+ T cells in Schistosoma japonicum (S. japonicum)-infected mice. PMID: 27792733
  36. Findings indicated that METH induced the upregulation of PD-1 expression which altered the cytokine production as well as cytotoxic functions in mouse model of lymphocytic choriomeningitis virus infection. PMID: 27760221
  37. Taken together, our data demonstrate the importance of CD40 signaling in the conversion of CTL exhaustion and its ability to enhance PD-1 antagonist action in rescuing exhausted CTLs in chronic infection. PMID: 28153727
  38. Our proteogenomic analysis demonstrates a role of Smad4 loss in the PD-L1 immune evasion, as well as Il1rl1's role in CSC-like properties of NCC-S1M. PMID: 28153736
  39. These studies indicate that PD-1 is a critical homeostatic regulator for Tregs by modulating proliferation and apoptosis during IL-2 therapy. PMID: 28151427
  40. data defined PD-1(hi)IL-25R(hi) as an early checkpoint in Innate lymphoid cell development; results provide a perspective for exploring PD-1 and its ligand (PD-L1) in immunotherapy, and allow effective manipulation of the immune system for disease prevention and therapy PMID: 27749818
  41. Authors demonstrate that inactivation of the PD-1 gene in melanoma-reactive CD8(+) T cells and in fibrosarcoma-reactive polyclonal T cells enhanced the persistence of PD-1 gene-modified T cells at the tumor site and increased tumor control. PMID: 27197251
  42. PD-1/PD-L1 plays a crucial role in maintaining immune tolerance induced by UVB-iDCs, as well as in actively controlling effector T cells specific to alloantigens. PMID: 27556047
  43. PD-1 dampens antigen-specific Th17 response, thus inhibiting autoimmune arthritis PMID: 27197661
  44. Tim-3(+) PD-1(+) CD8(+) T cells showed more evident properties associated with exhaustion than Tim-3(-) PD-1(+) CD8(+) T cells. PMID: 26750587
  45. that porcine islet-specific tolerance is dependent on PD-1, which could not be extended to skin grafts PMID: 26109574
  46. Programmed cell death-1 engagement followed by zymosan stimulation might primarily attenuate the phosphorylation of tyrosine residue in Programmed cell death-1 receptor/ligand. PMID: 26913605
  47. these data suggest a scenario in which microglia are involved in the regulation of experimental autoimmune encephalomyelitis by suppressing Th1-cell differentiation via the PD-L1-nitric oxide pathway. PMID: 26769487
  48. Blockade of TGFbeta downregulated PD-1 and PD-L1 expression and precipitated graft rejection. PMID: 26824266
  49. PD-1 regulates peripheral T-cell responses in both human and murine rheumatoid arthritis PMID: 26608464
  50. Decidual NK, NKT and gamma/delta T cells showed increased PD-1 expression and reduced cytotoxic potential when compared to the periphery. PMID: 26278059

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type I membrane protein.
Tissue Specificity
Thymus-specific.
Database Links
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X